All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Bookmark this article
The Multiple Myeloma Hub is pleased to present a visual abstract representing data from a retrospective multi-country study evaluating treatment patterns in patients with relapsed/ refractory multiple myeloma (RRMM) initiating third-line therapies. Data were collected from patients in Germany, France, Italy, Spain, and the United Kingdom (UK).
The most common third-line treatments by country were recorded by class and agent, as well as comparisons made between historical (2016–2018) and more recent (2019–2021) treatment regimens. The trends identified between countries suggest that physician’s choice of treatment for RRMM varies significantly; however, there is a trend toward triplet regimens in the latest recorded data.1
To download this visual abstract, click below.Download here
EHA2023 abstracts: What's hot in multiple myeloma and other plasma cell dyscrasias?
To help navigate the exciting content being presented at the EHA2023 Congress, the Multiple Myeloma Hub Steering Committee have provided their recommendations for the...
IMWG recommendations for infections in multiple myeloma
Infection is a major concern in patients with multiple myeloma (MM), leading to morbidity and mortality, and it may occur due to several reasons. Infection risk is highest within the first 3...
Subscribe to get the best content related to multiple myeloma delivered to your inbox